Skip to content
Homepage
Author:
Verismo Therapeutics
Posted Date:
May 24, 2026
Verismo Therapeutics Presents Preclinical Data at AACR 2026 for SynKIR™-310 KIR-CAR Indicating Superior Preclinical Activity in B Cell Malignancies and Early Clinical Efficacy
Verismo Therapeutics
May 24, 2026
Verismo Therapeutics’ Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session
Verismo Therapeutics
May 24, 2026
Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
Verismo Therapeutics
May 23, 2026
Verismo Therapeutics to Present Novel Multi-chain KIR-CAR Data – Including Initial Clinical Trial Results for Lead Immuno-Oncology Candidates SynKIR™-110 and SynKIR™-310 – at AACR Annual Meeting 2026
Verismo Therapeutics
May 20, 2026
